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Abstract
Background: The malaria parasite Plasmodium falciparum EBA-175 binds its receptor sialic acids on glycophorin A when
invading erythrocytes. The receptor-binding region (RII) contains two cysteine-rich domains with similar cysteine motifs (F1
and F2). Functional relationships between F1 and F2 domains and characterization of EBA-175 were studied using specific
monoclonal antibodies (mAbs) against these domains.
Methods and Findings: Five mAbs specific for F1 or F2 were generated. Three mAbs specific for F2 potently blocked
binding of EBA-175 to erythrocytes, and merozoite invasion of erythrocytes (IC50 10 to 100 mg/ml IgG in growth inhibition
assays). A mAb specific for F1 blocked EBA-175 binding and merozoite invasion less effectively. The difference observed
between the IC50 of F1 and F2 mAbs was not due to differing association and disassociation rates as determined by surface
plasmon resonance. Four of the mAbs recognized conformation-dependent epitopes within F1 or F2. Used in combination,
F1 and F2 mAbs blocked the binding of native EBA-175 to erythrocytes and inhibited parasite invasion synergistically in
vitro. MAb R217, the most potent, did not recognize sporozoites, 3-day hepatocyte stage parasites, nor rings, trophozoites,
gametocytes, retorts, ookinetes, and oocysts but recognized 6-day hepatocyte stage parasites, and schizonts. Even though
efficient at blocking binding to erythrocytes and inhibiting invasion into erythrocytes, MAb R217 did not inhibit sporozoite
invasion and development in hepatocytes in vitro.
Conclusions: The role of the F1 and F2 domains in erythrocyte invasion and binding was elucidated with mAbs. These mAbs
interfere with native EBA-175 binding to erythrocyte in a synergistic fashion. The stage specific expression of EBA-175
showed that the primary focus of activity was the merozoite stage. A recombinant RII protein vaccine consisting of both F1
and F2 domains that could induce synergistic activity should be optimal for induction of antibody responses that interfere
with merozoite invasion of erythrocytes.
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The invasion of erythrocytes by malaria parasites is mediated by
specific molecular interactions between erythrocyte receptors and
parasite ligands. Within Plasmodium sp., a family of erythrocyte
binding proteins (EBPs) with signature cysteine rich motifs is
involved in binding to erythrocyte receptors for invasion of
erythrocytes [1–4] or sequestration of parasitized erythrocytes to
endothelial cells [5–7]. EBA-175 is a 175 kDa erythrocyte binding
protein [1,4,8,9], that binds erythrocytes via sialic acids on its
receptor glycophorin A. This binding involves recognition of both
the sialic acids and the peptide backbone of glycophorin A [4].
The erythrocyte-binding region of EBA-175 is a 616 amino acid
fragment, designated region II (RII) that contains 27 cysteines as
tandem duplications of two copies of a cysteine rich domain to
form regions F1 and F2 [2]. F1 and F2 are homologous to the
Duffy binding protein of P. vivax and are also called Duffy binding-
like domains (DBL). The presence of one or two DBL domains
and other elements including a C-terminal cysteine-rich region
and a type I transmembrane domain classifies EBA-175 as a
member of the erythrocyte binding-like (EBL) superfamily of
proteins [2]. This EBL superfamily includes BAEBL/EBA-140/
EBP2 [10-12] MAEBL [13], EBA-181/JESEBL [14]and var genes,
a large family of genes regulated by chromatin modification
[15,16] that encode antigenically variant proteins including
PfEMP-1 [5,7]. PfEMP-1 contains several DBL domains and is
involved in the cytoadherence of parasitized erythrocytes to
endothelia of microcapillaries causing cerebral malaria and
mortality associated with P. falciparum. Thus the RII of EBA-175
that consists of two DBL domains that appear unique to
Plasmodium sp. may constitute a good target for rational drug
design and vaccines.
Antibodies generated against EBA-175 RII potently block the
binding of native EBA-175 to erythrocytes [17–19] and even inhibit
invasion of P. falciparum strains that invade erythrocytes by pathways
that do not require sialic acids for invasion in vitro [18]. Further, a
DNA prime/recombinant protein boost immunization regimen was
shown to protect 3 of 4 Aotus monkeys against a lethal P. falciparum
blood-stage challenge [17]. Immunoglobulin G obtained from the
vaccinated Aotus monkeys inhibited parasite growth in vitro [17]. F2
alone is sufficient for binding to erythrocytes [4]. Indeed,
crystallographic studies show that binding to glycophorin A occurs
when a dimer arrangement of RII forms a channel allowing ligand-
receptor interaction wherein more than 75% of the sequences
within the channel are derived from F2 [20]. The EBA-175 RII
DNA vaccine tested in non-human primates [17,19] and recom-
binant protein vaccine tested in a Phase 1 clinical trial [21] are
comprised of both F1 and F2 domains.
In this report we investigated the role of EBA-175 RII F1 and F2
domains in erythrocyte binding and parasite invasion in vitro using
monoclonal antibodies (mAbs) that specifically recognized F1 or F2
domains, and established the stage specific expression of EBA-175
in the parasite life cycle. Although RII specific mAbs blocked F2
function more efficiently than F1, we show that a combination of F1
and F2 specific mAbs blocked the function of EBA-175 erythrocyte
binding and parasite invasion in vitro, synergistically.
Results
Characteristics of MAbs generated
Five mAbs were cloned and identified as R215 through R218
and R256. All the mAbs were identified as belonging to subclass
IgG1. These mAbs gave a characteristic apical punctate
fluorescence pattern with FVO (Fig. 1A and Table 1) and 3D7
strain (not shown) late stage schizonts. The specificity of the mAbs
against EBA-175 was determined by immunoprecipitation of P.
falciparum [
35S]-metabolically labeled schizont stage parasite
culture supernatant containing labeled native EBA-175 (Fig. 1B)
as well as schizont-infected erythrocyte lysates (not shown). MAbs
R216, R217 and R218 recognized a 175 kDa protein, R216 albeit
poorly, that was similar in mass to EBA-175 as recognized by
rabbit polyclonal anti-EBA-175 RII (KLS13) used as a positive
control (Fig. 1B) [18], and negative control KLS15, rabbit
polyclonal sera raised against adjuvant alone. The isotype control
mAb 48F8, a mAb raised against adjuvant alone did not
immunoprecipitate EBA-175 (Fig. 1B). The IFA staining patterns
of mAbs R215, R216, R218 and R256 and results of
immunoprecipitation with mAbs R215 and R256 were similar to
that with mAb R217, respectively (data not shown).
Immunoblot analysis using both reduced and non-reduced
conditions showed that mAbs R217 (Fig. 2), R215 and R256
(data not shown) recognized a conformational, disulfide-con-
strained epitope located within the F2 domain of RII. This is
because R217 only recognized non-reduced F2 domain of RII.
MAb R218 recognized a conformation-dependent epitope
located within the F1 domain of RII because only the F1 domain
was recognized. Even though similar quantities of F1 and F2
protein were present in the immunoblot, the recognition was
much stronger against non-reduced F1, probably because
reduction was incomplete. MAb R216 most probably recognized
a linear or unexposed region of the F2 domain of RII because
only F2 was recognized. Even though similar quantities of F2
protein were present in the immunoblot, the recognition was
much stronger against reduced F2 (Fig. 2). Slight recognition of
non-reduced F2 was seen with R216 probably because there was
some denaturation and reduction in the material. Further analysis
of RII/F2 specific mAbs R215, R216, R217 and R256
demonstrated that R215, R217 and R256 competed with each
other for binding recombinant RII protein by competition ELISA
(data not shown).
MAbs generated blocked the binding of native EBA-175
to erythrocytes and inhibit invasion and growth of
parasites in vitro
Differences in the ability of recombinant F1 and F2 domains to
bind erythrocytes have been reported [4,22]. When expressed on
the surface of COS cells, F2 alone could support the binding and
rosetting of erythrocytes on the surface of these COS cells, but not
F1 alone [4]. Hence we investigated whether targeting F1 and F2
in combination would have an additive or synergistic effect on
blocking of EBA-175 erythrocyte binding. Using IgG concentra-
tions within the range of the IC50’s for R217, R218 and R256
(Table 1), and [
35S]-metabolically labeled native EBA-175,
blocking of binding studies were performed such that the
proportion of mAb R217 equaled one minus the proportion of
mAb R218 or R256. MAbs R217 and R256, both against the F2
domain, blocked [
35S]-labeled native EBA-175 binding to
erythrocytes efficiently with IC50 of 1-15 ng/mL IgG (Fig. 3 and
Table 1). The MAb R218 against the F1 domain had a lesser
ability to block the binding of native EBA-175 to erythrocytes
(IC50 ranged between 25 to 125 ng/mL IgG, (Fig. 3 and Table 1).
Interestingly, MAb R216 that recognizes a linear or unexposed
epitope essentially could not block binding of native EBA-175 to
erythrocytes at the maximal amount of MAb R216 used in our
binding assay. In fact, the IC50 was only 14% and 21% at 333 and
666 mg/mL R216 (data not shown). When the F2 specific mAb
R217 is proportionally mixed with the F1 specific mAb R218, a
synergistic increase in blocking is evident (Fig. 3, panel A). Under
Inhibitory Monoclonals against EBA-175 Region II
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with mAb R256 both of which are most probably against a
common region in F2 together resulted in an additive effect such
that there was no overall increase in blocking (Fig. 3, panel B).
We investigated whether RII specific mAbs conferred growth
inhibitory activity (GIA) on the parasite strains 3D7 and FVO. We
selected the 3D7 strain that invades neuraminidase-treated
erythrocytes, which are devoid of sialic acids, at 70% efficiency as
compared to invasion of normal erythrocytes [23], and the FVO
strain that is dependent on sialic acids for erythrocyte invasion [18].
The results of 5 separate growth inhibition assays are shown in
Table 2 for mAbs R216, R217 and R218 and summarized for the
FVO strain in Table 1. GIA results obtained for mAb R256 (data
not shown) were similar to mAb R217. A dose dependent effect on
parasite growth was observed with mAb R217 against the FVO
strain (Fig. 4). The inhibition of parasite growth per cycle of the
FVO strain compared to the 3D7 strain was approximately 2-fold
greater. The IC50 for mAbs R217 and R256 (data not shown)
against FVO ranged between 10 – 100 mg/mL IgG compared to
the IC50 against 3D7 which was greater than 1 mg/mL (Table 2).
Analysis of experimental conditions such as initial parasitemias and
growth rates were similar and thus could not result in the consistent
differences in inhibition of parasite growth between FVO and 3D7
strains (data not shown). Additional growth inhibition studies using
mAbs R216 and R218, which recognized a linear or hidden epitope
within F2 or a conformation-dependent epitope within F1 respec-
tively, demonstrated that both significantly inhibited parasite
growth although markedly less than mAb R217 (Table 2).
Association and dissociation rates of mAbs R217 and
R218 are similar
Since F1 and F2 domains have different avidities for binding
human erythrocytes when transiently expressed on the surface of
COS cells [4], we were interested in determining whether these
differences could be probed using R218 and R217 that were against
domains F1 and F2 respectively. Using surface plasmon resonance,
we determined that the association and dissociation rates for mAbs
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mAb R218 that was not observed in our other assays. The kds for
mAbs R217, R218 and R256 which were in the nanomolar or
picomolar range are reported in Table 1.
P. falciparum sporozoites do not express EBA-175 (Fig. 5)
Immunofluorescence assays using mAb R217 against infectious
P. falciparum sporozoites harvested from mosquito salivary glands and
schizont infected human erythrocytes revealed that EBA-175 is
expressed in mature schizonts (Fig. 1and Fig. 5C), and as described
previously [1], but not in sporozoites (Fig. 5B). R217 mAb failed to
show any reactivity in IFA with sporozoites even when used at a
concentration of 20 ug/mL (data not shown). In contrast, these
Figure 1. EBA-175 RII mAbs generated against baculovirus expressed recombinant EBA-175 RII protein recognizes native EBA-175.
Panel A: Dual immunofluorescent analyses showing apical staining of mature P. falciparum (FVO strain) schizont with EBA-175 RII specific mAb R217
used at 10 ug/mL and rabbit polyclonal sera KLS13 against baculovirus expressed EBA-175 RII (used at 1:200 dilution). Panel B: Phosphoimager
detection of parasite culture supernatant containing [35S]-labeled native EBA-175 immunoprecipitated with mAbs and polyclonal sera. MAb R216,
R217, R218 and KLS13 (polyclonal sera against EBA-175 RII) immunoprecipitated native EBA-175, whereas mAb 48F8 (isotype control) and polyclonal
sera KLS15 raised against Freund’s adjuvant did not.
doi:10.1371/journal.pone.0018393.g001
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P. falciparum circumsporozoite protein used at 0.136 ug/mL (Fig. 5A).
EBA-175 is expressed in late hepatic stages (6 day) of
P.falciparum, but not in early (3 day) hepatic stages in
vitro (Fig. 5)
P. falciparum sporozoites when allowed to invade human
HCO4 cells [24] in vitro, developed to 6 day liver stage parasites
that express EBA-175 (Fig. 5F) . At 6 days after invasion of
sporozoites, these liver stage parasites also strongly express MSP-1
(data not shown). In contrast, the earlier liver stage parasites 3 days
after invasion of sporozoites, neither express EBA-175 nor MSP-1.
MAb R217 recognized late (6 day) liver stage parasites that are
probably merozoites with typical punctate fluorescence (Fig. 5F)
prior to erythrocyte rupture, but did not recognize early (3 Day)
hepatic stage parasites (Table 3).
MAb R217 does not effect the invasion and development
of P. falciparum sporozoites in human hepatocytes in
vitro as assessed by the inhibition of liver stage
development assay (ILSDA) (Table 4)
In ILSDA, mAb 2A10 against the P. falciparum CSP reduced the
numbers of parasites expressing PfLSA-1 by 92.83%. In the same
assay mAb R217 had no effect on the number of parasites
expressing PfLSA-1 (Table 4).
MAb 217 recognizes schizonts but not rings,
trophozoites nor male and female gametocytes, retorts,
ookinetes and oocysts
MAb 217 recognizes segmenters and merozoites in mature
schizonts (Fig. 1A and Fig. 5C) but not early rings that develop just
after invasion (2–6 hours), nor rings and earlier trophozoites (data












R215 IgG1 + F2c
1 + - + ND ND ND
R216 IgG1 + F2L Poor + -** ND NA NA
R217 IgG1 + F2c
1 + - + 1.84610
29 1–15 10–100 mg/ml
R218 IgG1 + F1c + -* + 1.53610
211 25–125 .1 mg/ml
R256 IgG1 + F2c
1 + - + 1.8610
210 1–15 10–100 mg/ml
ND: not determined
NA: not achievable. R216 at 333 and 666 mg/ml IgG blocked EBA-175 binding by 14 and 21%, respectively.
# P. falciparum FVO 2 cycle suspension growth inhibition assay (GIA).
1mAbs compete against each other for binding RII by competition ELISA.
c: constrained epitope; L: linear epitope; immppt: immunoprecipitate.
*incomplete reduction; ** partial denaturation/reduction.
doi:10.1371/journal.pone.0018393.t001
Figure 2. Immunoblot analysis of EBA-175 RII mAbs against P. pastoris expressed recombinant RII F1 or F2 domains. MAb R216
recognized a linear epitope within the F2 domain reacting against both reduced recombinant RII and F2 domain. MAb R217 recognized an epitope
within F2 that was conformationally dependent. Reduction abrogated reactivity of R217 against recombinant RII and the F2 domain. MAb R218 was
conformationally dependent and specific against the F1 domain and reacted against non-reduced RII and F1. Purified recombinant baculovirus EBA-
175 RII protein at 0.5 mg per lane, or 10 uL per lane of supernatant of P. pastoris cultures expressing recombinant EBA-175 RII F1 or F2 domains were
separated by SDS-PAGE under reduced or non-reduced conditions and electroblotted onto nitrocellulose membranes. In analyses against R216, a
small fraction of the recombinant proteins were slightly denatured or reduced. In analysis using R218, reduction of the recombinant proteins was not
absolute. Membranes were probed with 10 ug/mL each of mAbs R216, R217 or R218 separately. A similar staining pattern to that of R217 was
observed for mAbs R215 and R256 (data not shown).
doi:10.1371/journal.pone.0018393.g002
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development (stages I-V), retorts, ookinetes and oocysts are also
not recognized by mAb 217 but these preparations are all
recognized by monoclonal antibody against Pfs25 (from MR4,
data not shown)[25].
Discussion
RII is a 616 amino acid fragment of EBA-175 that consists of
two cysteine-rich Duffy binding-like (DBL) domains (F1 and F2)
that are homologous to the RII of Duffy binding protein of P. vivax.
EBA-175 RII is the receptor-binding domain that binds sialic acids
on its receptor, glycophorin A, on erythrocytes during merozoite
invasion. Polyclonal antibodies from mice, rabbits and Aotus
monkeys immunized against RII block native EBA-175 binding to
erythrocyte and inhibit parasite growth in vitro [1,19]. Here we
report on the characterization of a panel of EBA-175 RII specific
mAbs that both alone or in combination block the binding of
native EBA-175 to erythrocytes and inhibit P. falciparum growth in
vitro.
Five mAb clones designated R215 through R218 and R256
were developed against a purified baculovirus expressed RII
(3D7 strain) protein [22] that recognized either linear (R216) or
conformationally dependent (disulfide constrained) epitopes
within F1 (R218) or F2 (R215, R217 and R256) as shown by
immunoprecipitation (Fig. 1B) and immunoblot (Fig. 2). All of
the mAbs recognized P. falciparum FVO and 3D7 schizont
infected erythrocytes in standard fixed immunofluorescence
assays. These strains were selected for testing because 3D7 can
invade via sialic acid independent pathway(s) while FVO strictly
invade by binding to sialic acids. All but one of the mAbs (R216)
effectively blocked native EBA-175 binding and inhibited
parasite growth in vitro (Table 1). MAb R216 was incapable of
blocking the binding of native EBA-175 to erythrocytes and was
also not able to inhibit in GIA (Table 1). The difference seen
between mAb R216 and the other biologically active mAbs is
likely due to R216 recognizing a linear or hidden epitope.
Reactivity of mAb R216 to reduced recombinant RII in
immunoblots show increased recognition as compared to non-
reduced recombinant RII (Fig. 2). MAb R218 that recognized
the F1 domain inhibited parasite growth considerably less than
the F2 domain specific mAbs. Surface plasmon resonance
association and dissociation rates revealed nanomolar or greater
KDs for mAbs R217, R218 and R256 indicative of high affinity
binding (KDs: 0.01–1 nM) (Table 1). Thus the observed
differences in inhibition of parasite growth by the mAbs were
Figure 3. MAbs against the F1 and F2 domains block native [
35S]-labeled EBA-175 binding to erythrocytes synergistically. Effects of
mAbs on immunoprecipitation of [
35S]-labeled parasite culture supernatant containing labeled native EBA-175. Panel A shows that ratios of mAb
R217 (against F2) and R218 (against F1) together increased the blocking of native EBA-175 binding (a synergistic effect). In contrast, Panel B shows
that different ratios of mAb R217 (against F2) and R256 (also against F2) together resulted in similar levels of blocking (an additive effect). R217 and
R256 may recognize a common epitope within the F2 domain. Bars show % blocking values as assessed by a phosphoimager.
doi:10.1371/journal.pone.0018393.g003
Figure 4. Scatterplot showing a dose effect on P. falciparum FVO
growth using mAb R217. The solid line shows the linear regression
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which recognizes the F1 domain, is less able to inhibit parasite
invasion because its recognition epitope is a region of F1that is
not involved intimately with receptor binding. Structural studies
of RII showed that F1 and F2 domains are very similar, and that
RII crystallizes as a dimer which interacts extensively with each
other in an antiparallel fashion resembling a handshake [20].
The F1 domain of one monomer interacts directly with the F2
domain of the other monomer. The formation of the RII dimer
creates two channels that span the dimer with 75% of the
residues that comprise the channel surfaces contributed by the
F2 domain. Thus F1 is not physically involved in the binding but
stabilizes the RII dimer complex required for docking of EBA-
175 as it interacts with its receptor glycophorin A, as described
in crystallographic studies [20].
Invasion of erythrocytes by the FVO strain is dependent on the
presence of sialic acids on glycophorin A while 3D7 can invade
by alternate pathways other than sialic acids. In the case of 3D7,
antibodies against RII could nevertheless still significantly block
invasion of erythrocytes [18,26]. In this report we show that the
F2 specific mAb R217 clearly blocked the invasion of the FVO
strain approximately 2-fold greater relative to the 3D7 strain
(Table 2). The RII amino acid sequences of the FVO versus the
3D7 strains only differ by 5 out of the 616 amino acid residues
[27]. We thus argue that the reduced inhibition of invasion is due
to the ability of 3D7 parasites to invade erythrocytes via an
alternate pathway that does not involve sialic acids. MAb R217,
on the other hand blocked the invasion of FVO parasites
efficiently since FVO parasites exclusively use sialic acids on
glycophorin A for invasion.
EBA-175 is most efficiently harvested from spent culture media
of ruptured schizonts [8]. The fact that EBA-175 was a type I
membrane protein [1] localized in micronemes [28] that was not
primarily exposed, was confounding. More recently, it was shown
that PfROM4, a rhomboid protease, specifically cleaves EBA-175
upon merozoite invasion of erythrocytes a process essential for
further development of the parasite [29]. It remains to be
elucidated whether the docking of the EBA-175 dimer bound to
glycophorin A [20] and the release of EBA-175 from the
merozoite by PfROM4 is a stepwise or simultaneous event.
Obviously, the fact that mAb 217 and the other RII mAbs so
efficiently inhibit invasion and binding argues that the functional
EBA-175 molecules are those in close contact at the erythrocyte
surface. It remains to be explained why mAb R217 blocks the
invasion of sialic acid independent strains [18] even though
PfROM4 cleaves EBA-175 equally in both sialic acid dependent
and independent strains [29].
EBA-175 is expressed in the micronemes of merozoites in
schizonts [28] probably as early as nascent segmenting stages in
both liver stage and asexual stage schizonts. It had previously been
reported that EBA-175 is expressed in sporozoites, a conclusion
from studies of reverse transcription of sporozoite total RNA as
well as immunofluorescence of sporozoites using polyclonal
antibody raised against a recombinant fragment of EBA-175
[30]. We show that mAb R217 does not recognize sporozoites by
IFA (Fig. 5) and does not recognize parasites developing in
infected hepatocytes 3 days after infection with P. falciparum
sporozoites (Table 4), nor developing and mature male and female
gametocytes (all stages 1-V), retorts, ookinetes and oocysts.
However, EBA-175 is clearly expressed in parasites developing
in hepatocytes 6 days after sporozoite infection, at a time when
these liver stage schizonts are close to being ready to rupture
(Fig. 5F, Table 3). In summary, we find no evidence of sporozoite
or early liver stage expression of EBA-175 using our characterized
mAbs specific against EBA-175 RII. Our studies use preparations
of sporozoites that are aseptic and purified from mosquito salivary
gland material produced in conditions that meet regulatory
compliance for production of clinical material, and liver assays
that are used for assessment of such sporozoites [31]. The
sporozoites used are characterized in terms of purity and asepticity
Table 2. Inhibition of growth of P. falciparum FVO and 3D7 strains by RII MAbs.
Exp. # mAb (mg/ml) FVO infected RBCs (%) 3D7 infected RBCs (%)
48F8 (Control) R217 R216 48F8 (Control) R217 R216
Pc* Pt (Ipc)** Pt (Ipc) Pc Pt (Ipc) Pt (Ipc)
1 1.0 1.64 0.28 (59) 1.53 (4) 5.43 3.29 (22) 3.97 (14)
2 1.0 0.56 0.11 (57) 0.43 (13) 4.16 2.11 (29) 3.09 (14)
3 1.0 2.26 0.36 (60) ND 5.38 3.16 (23) ND
0.32 2.34 0.63 (48) ND 5.13 3.21 (21) ND
0.10 2.14 0.87 (36) ND 5.18 3.23 (21) ND
0.03 2.40 1.52 (20) ND 5.41 4.14 (12) ND
0.01 2.51 1.67 (19) ND 5.25 4.62 (6) ND
48F8 (Control) R217 R218 48F8 (Control) R217 R218
4 1.0 0.97 ND 0.65 (18) 3.15 ND 3.02 (2)
0.5 1.06 0.22 (55) 0.75 (16) 3.10 ND 3.15 (21)
5 1.0 0.26 0.04 (60) 0.19 (14) 2.94 ND 2.82 (2)
0.5 0.27 0.07 (50) 0.17 (20) 2.96 ND 2.86 (2)
0.25 0.24 0.06 (50) 0.22 (6) 2.99 ND 2.79 (3)
*Pc: final parasitemia after two cycles of invasion in presence of control mAb 48F8.
**Pt (Ipc): final parasitemia after two cycles of invasion in presence of test mAb (calculated % inhibition per invasion cycle).
The percentage inhibition per cycle was calculated according to the formula: Ipc = 1 – (Pt/Pc)
K.
doi:10.1371/journal.pone.0018393.t002
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discrepancy between our results and those of Gruner et al [30].
The mAb reagents specific for EBA-175 RII described here if
used together with EBA-175-GFP chimeric parasites [32] could be
powerful tools that can be used to probe the role of EBA-175 in
merozoite invasion of erythrocytes and may lead to the design of
improved receptor interfering drugs and vaccines.
Materials and Methods
Ethics Statement
All animal studies were done in compliance with protocols
approved by the Animal Care and Use Committee at EntreMed
Inc., 9640 Medical Center Dr., Rockville MD 20850, under
approved protocol ID No. ENT018.
Figure 5. EBA-175 is expressed in P.falciparum schizonts, and late liver stages in human hepatocytes in vitro, but not sporozoites.
A) Sporozoites stained with anti-PfCSP mAb 2A10 (used at 0.136 ug/mL), B) sporozoites stained with mAb R217 (used at 300 ug/mL), C) schizont
stained with mAb R217 (used at 2.34 ug/mL), M: merozoite; A: apical end of the merozoite expressing EBA175, D) schizont stained with anti-PfCSP
mAb 2A10 (used at 68 ug/mL). The nuclei were stained with DAPI, E) HC-O4 human hepatocytes stained with anti-P.falciparum liver stage antigen -1
(PfLSA-1) polyclonal rabbit serum (1:50 dilution) 6 days post infection with P.falciparum sporozoites, F) HC-O4 human hepatocytes stained with mAb
R217 (used at 100 ug/mL) 6 days post infection with P.falciparum sporozoites. N: nucleus of the hepatocyte; P: liver stage parasite.
doi:10.1371/journal.pone.0018393.g005
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Plasmodium falciparum 3D7 strain and FVO strain (Aotus adapted)
were maintained as previously reported [33]. Schizonts were
purified on Percoll density gradients [34]. P. falciparum FVO strain
was metabolically labeled with TRAN
35S-LABEL
TM (ICN
Radiochemicals, Irvine, CA) as previously described [4]. Cell
pellets and supernatant were stored at 270uC for later use.
Animals and immunizations
BALB/c mice were immunized subcutaneously with 50 mg
each of purified baculovirus derived RII protein (3D7) [22]
in Freund’s complete and incomplete adjuvant as suggested
by the manufacturer (Sigma, St Louis, MO). Mice were
immunized on days 0, 14, and 28 and bled on days, 21, 12, 26,
and 40.
Monoclonal Antibodies
MAbs were produced using spleen cells obtained from BALB/c
mice immunized with purified baculovirus recombinant EBA-175
RII protein (3D7) [22], and fused with Sp2/0-Ag14 myeloma
cells [35]. Hybridoma culture supernatants were screened by
indirect immunofluorescence assay (IFA) against methanol-fixed
parasitized (3D7) erythrocytes prepared on 15 well slides.
Immunoglobulin G was detected using a goat anti-mouse IgG
(c) chain specific FITC coupled reagent (Kirkegaard & Perry
Laboratories, Inc., Gaithersburg, MD). Supernatants positive by
IFA were screened for blocking of [
35S]-metabolically labeled
EBA-175 erythrocyte binding [4]. Hybridoma cell lines positive
by IFA and that blocked native EBA-175 erythrocyte binding to
erythrocytes were cloned twice by limiting dilution. Ascites was
produced in nude mice (Harlan Bioproducts for Science, Inc.,
Madison, WI). IgG was purified from ascites by Protein G
column chromatography using the ImmunoPure Buffer System
(Pierce, Rockford, IL). IgG subclasses were determined by ELISA
using a mouse monoclonal antibody isotyping kit (Sigma, St.
Louis, MO) as suggested by the manufacturer. The specificity and
growth inhibitory activity of the rabbit polyclonal antibodies
produced against recombinant EBA-175 RII has been reported
[18].
Immunoprecipitation, immunoblot and erythrocyte
blocking of binding studies
Aliquots of approximately 1610
8 parasitized (3D7) erythrocytes
that had been metabolically labeled for 4 hours were extracted in
buffer containing 1% Triton X-100, [36,37]. Samples were
immunoprecipitated by coupling each mAb to Protein G-
Sepharose (GE Healthcare) and the immunoprecipitates were
washed as previously described using a buffer containing Triton
X-100. The labeled proteins were resolved by SDS-PAGE and
detected using a phosphoimager (BioRad Molecular Imager FX,
Hercules, CA). Immunoblots using the baculovirus recombinant
EBA-175 RII protein as well as recombinant F1 and F2 domains
expressed in methylotrophic yeast Pichia pastoris were prepared as
described previously [22]. EBA-175 erythrocyte blocking of
binding studies and the determination of the IC50 for blocking
of EBA-175 binding were performed as previously described,
respectively [4,17].
Immunofluorescence Assay
Indirect immunofluorescence assays for screening and selec-
tion of monoclonal antibody producing clones were performed
essentially as described [12] using mouse or rabbit specific
antibodies coupled to Alexa 488 or Alexa 546 (Molecular Probes,
Eugene, OR), respectively. For other assays including sporozo-
ites, asexual stages including schizonts, male and female
gametocytes, retorts and ookinetes and liver stages, parasites
Table 3. Expression of P. falciparum EBA-175 in late (6 day) but not in early (3 day) liver stages.
Sporozoites/well Primary Antibody*
Days in
culture Number of liver stages
Mean (liver
stages)/well STDEV % CV
Well 1 Well 2 Well 3
25,000 PfLSA-1 3 309 342 326 325.67 16.50 5.07%
R217 3 0 0 0 0.00 0.00 0.00%
50,000 PfLSA-1 6 32 57 41 43.33 12.66 29.22
R217 6 18 26 12 18.67 7.02 37.63
*PfLSA-1 polyclonal rabbit antibody used at 1:50 dilution and mAb R217 used at 100 ug/mL.
doi:10.1371/journal.pone.0018393.t003
Table 4. MAb R217 does not inhibit invasion and development of P. falciparum sporozoites in the human hepatocyte line, HC04 as
assessed by ILSDA.
Test Material Number of Parasites Expressing PfLSA-1*
% Inhibition
(compared to Medium)
Well 1 Well 2 Well 3 Mean SD
Medium (control) 309 342 320 325.7 16.50 NA
Anti-PfEBA-175 mAb R217 (100 ug/ml) 367 331 314 337.3 27.06 0
Anti-PfCSP mAb 2A10 (100 ug/ml) 18 30 22 23.3 6.11 92.83
*PfLSA-1 polyclonal rabbit antibody used at 1:50 dilution.
doi:10.1371/journal.pone.0018393.t004
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performed on 12-well Cel-Line Brand IFAT slides (Erie
Scientific), containing air-dried sporozoites, or methanol fixed
asexual stages including schizonts, and sexual stage parasites in
infected human erythrocytes. For liver stage parasites, slides were
incubated in a moist chamber at 37uCf o r1h o u rw i t h2f o l d
diluted (starting from 1:50) monoclonal antibodies, R217 and
2A10 (mAb against PfCSP) in 1XPBS containing 1% BSA and
0.001% saponin. Slides were washed three times, five minutes
each, with 1X PBS and then incubated for 1 h at 37uCw i t h
Alexa Fluor 594 anti-mouse antibody at a dilution of 1:200 in
1XPBS containing 1% BSA and 0.001% saponin and 4’, 6-
diamidino-2-phenylindole (DAPI, 40 mg/mL) or Alexa Fluor 488
anti-mouse antibody (Green) at a dilution of 1:200 in 1XPBS
containing 1% BSA and 0.001% saponin. After three washes in
1X PBS, slides were mounted with Vectashield mounting
medium and observed under phase contrast at X1000 magni-
fication.
Surface Plasmon Resonance (BIAcore)
The KDs for RII binding by mAbs R217, R218 and R256
were determined using a BIAcore 3000 (BIAcore, Piscataway,
NJ). Purified recombinant RII was immobilized on the flow cell
of a CM5 BIAcore biosensor chip. The running buffer was
HSB-P buffer (10 mM HEPES [pH 7.4], 150 mM NaCl,
0.005% polysorbate 20 adjusted to 1 mM MgCl2) (BIAcore).
All measurements were determined at 25uC. The Langmuir
method from BIAevaluation 3.0 was used for determination of
KDs [38].
Asexual stage parasite growth inhibition studies
Asexual stage parasite growth inhibition studies were performed
as previously described [39]. Briefly, synchronized cultures of
P. falciparum schizont-infected erythrocytes were mixed with test or
control Protein G purified immunoglobulin G (IgG) so that final
IgG concentrations were as reported and the hematocrit was 6%.
The micro-culture plates were harvested for flow cytometry and
stained with Hoechst dye to detect parasite DNA. Percent
inhibition was calculated from the mean parasitemias of triplicate
test and control wells as 1006(control – test)/control. Polyclonal
rabbit anti-EBA-175 RII IgG was used as a positive control for all
experiments (data not shown) [18].
In vitro Inhibition of Liver Stage Development Assay
(ILSDA)
ILSDA was performed as described previously [40,41] with
some modifications. 4610
4 human hepatocyte HCO4 [24] cells
in D-MEM/F12 complete medium containing 10% fetal bovine
serum were seeded in each well of 8-well LabTek slides. After
about 16 hours, medium were aspirated from the wells and
2.5610
4 sporozoites (NF54) were mixed with either 100 ug/mL
anti-PfCSP mAb 2A10 or 100 ug/mL mAb R217 in 50 uL, and
added to each well. Triplicate wells were set up. Three wells of a
slide received sporozoites in 50 uL medium only (medium
control). Cultures were incubated at 37uC, 5% CO2 for 3 hours.
Wells were then washed thrice with medium, after which they
were replenished with 300 uL media, and returned to incuba-
tion at 37uC, 5% CO2. Medium was replaced with fresh
medium daily. At 72 hours, wells of the slide were washed
with 1X PBS thrice and fixed with ice-cold absolute methanol
for 10 minutes at room temperature. Fixed slides were
washed thrice with 1X PBS. Each well of the slide was
incubated with rabbit serum containing polyclonal antibodies
against P. falciparum liver stage antigen-1 (PfLSA -1) at 1:50
dilution followed by Alexa Fluor 488 anti-rabbit secondary
antibody. Slides were mounted with Vectashield and viewed
using an epifluorescent microscope. The numbers of parasites
expressing PfLSA-1 (p) present in each well were counted




where x = Mean number of (p) in medium control wells
where y = Mean number of (p) in Test mAb wells
Expression of EBA-175 in hepatic stages of P. falciparum
in human hepatocytes in vitro
Early hepatic stage (3 day) assay. LabTek chamber slide
wells were seeded with 4610
4 HC-O4 cells. After twenty four
hours, 25,000 sporozoites were added to each well. Washing and
processing of slides were as described in the ILSDA above. After
3 days, wells were fixed and stained with either rabbit polyclonal
antiserum against P. falciparum LSA-1 (1:50 dilution) followed by
Alexa Fluor 488 anti-rabbit antibody or R217 (100 ug/mL),
followed by Alexa Fluor 488 anti-mouse antibody and assessed
as mentioned above. The numbers of parasites expressing
PfLSA-1 or PfEBA-175 in each well were counted.
Late hepatic stage (6 day) assay. LabTek chamber slide
wells were seeded with 4610
4 HC-O4 cells. After twenty four
hours, 50,000 sporozoites were added to each well, and processed
and maintained as above. After 6 days, wells were fixed and
stained with either rabbit antiserum against P. falciparum LSA-1
(1:50 dilution) followed by Alexa Fluor 488 anti-rabbit antibody or
mAb R217 (100 ug/mL), followed by Alexa Fluor 488 anti-mouse
antibody and assessed as mentioned above. The numbers of
parasites expressing PfLSA-1 or PfEBA-175 in each well were
counted.
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